Most, if not all of the rosacea research being done is being funded by pharmaceutical companies or what is called the skin industry who have a vested interest in rosacea. The only non profit organizations for rosacea doing any rosacea research are the NRS and the AARS (possibly others) who clearly state that on their financial reports that they are heavily funded by pharmaceutical companies that offers rosacea drug treatments. These non profits as well any just about all rosacea research is funded by the skin industry.  The skin industry includes not only pharmaceutical companies that offer rosacea treatments but also the cosmetic companies that offer over the counter treatments for rosacea.  Science is assumed to be researched in integrity, after all it is science. "Science is a systematic endeavor that builds and organizes knowledge in the form of testable explanations and predictions about the universe." [1] Research is the "creative and systematic work undertaken to increase the stock of knowledge". [2] Integrity is "the practice of being honest and showing a consistent and uncompromising adherence to strong moral and ethical principles and values." [3] While most science research is without question done in integrity, there is a small unknown percentage of dark science worth investigating that results in retractable published research papers due to fraud or other data misinformation. [4]  The Rosacea Research & Development Institute [RRDi] was formed for the purpose of engaging in novel rosacea research that rosacea sufferers want done which is totally in contrast to the current rosacea research being done by the skin industry. For example, if 10K members of the RRDi each donated a dollar and decided what should be researched on rosacea, this non profit organization could actually engage in a different direction than how the skin industry does their research for their own agenda.  While we appreciate any rosacea research being done, it would be incredible if enough rosaceans got together and actually funded their own rosacea research. Are you in? Join the RRDi.  End Notes [1] Science, Wikipedia [2] Research, Wikipedia [3] Integrity, Wikipedia [4] The Truth Police, BBC

JAAD Case Rep. 2023 Apr 11;36:32-33. doi: 10.1016/j.jdcr.2023.03.022. eCollection 2023 Jun. NO ABSTRACT PMID:37215297 | PMC:PMC10195851 | DOI:10.1016/j.jdcr.2023.03.022 {url} = URL to article

Int J Dermatol. 2023 May 22. doi: 10.1111/ijd.16717. Online ahead of print. ABSTRACT BACKGROUND: Facial erythema in rosacea is a troublesome embarrassing presentation with limited options of treatment. Daily brimonidine gel was shown to be an effective modality of treatment. Being unavailable in Egypt and the scarcity of objective evaluation of its therapeutic effect motivated the search for other alternatives. OBJECTIVE: To evaluate the use and effectiveness of topical brimonidine eye drops for the management of facial erythema in rosacea with the aid of objective assessment. METHODS: The study was conducted on 10 rosacea patients presented with facial erythema. Brimonidine tartrate eye drops 0.2% were applied twice daily for 3 months on areas of red facial skin. Punch biopsies were obtained before and after 3 months of treatment. Routine hematoxylin and eosin (H&E) staining as well as CD34 immunohistochemical staining were performed for all biopsies. Sections were examined to detect the changes in the count and the surface area of blood vessels. RESULTS: Evaluation of clinical results showed good improvement of facial redness at the end of treatment (55-75%). Only 10% of subjects expressed rebound erythema. H&E and CD34 stained sections showed an increased count of dilated dermal blood vessels, which decreased significantly after treatment in count and surface area (P = 0.005, and P = 0.004, respectively). CONCLUSION: Topical brimonidine eye drops proved to be effective in managing facial erythema in rosacea, providing an available and cheaper alternative to brimonidine gel. The study improved the subjective evaluation in the context of objective assessment of treatment efficacy. PMID:37212604 | DOI:10.1111/ijd.16717 {url} = URL to article